PTG 100

Drug Profile

PTG 100

Alternative Names: alpha4 beta7 integrin antagonist - Protagonist Therapeutics; PTG-100

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Protagonist Therapeutics
  • Class Anti-inflammatories; Disulfides; Peptides
  • Mechanism of Action Alpha4-beta7 integrin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • Phase I Inflammatory bowel diseases

Most Recent Events

  • 17 Jan 2017 Phase-II clinical trials in Ulcerative colitis in New Zealand, Canada, Europe, Australia, Asia, Australia, USA (PO) (NCT02895100)
  • 05 Jan 2017 Protagonist Therapeutics has patent protection for alpha4beta7 integrin peptide inhibitors in USA
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top